Drug Profile
Clostridium butyricum M588- Miyarisan Pharmaceutical
Alternative Names: Clostridium butyricum Miyairi 588 strain; CBM-588; Cdactin-O; CM588; Miya-BMLatest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator Miyarisan Pharmaceutical
- Class Antidiarrhoeals; Probiotics
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diarrhoea
Most Recent Events
- 16 Jun 2015 Phase II development is ongoing in the USA
- 04 Nov 2009 Clinical development is ongoing in USA
- 02 Nov 2005 Phase-II/III clinical trials in Diarrhoea in USA (PO)